Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Muscle Growth
Endogenous activin/myostatin binding protein — the gene-therapy myostatin inhibitor.
Peptide B
Muscle Growth
Truncated IGF-1 variant — site-specific, short-acting muscle growth signal.
Typical vial
1 mg
Typical dose
100-300 mcg
Half-life
~30 minutes (recombinant); years (AAV expression)
FDA status
Not FDA approved as recombinant protein. AAV-Follistatin gen…
Typical vial
1 mg
Typical dose
20-100 mcg
Half-life
~20-30 minutes
FDA status
Not FDA approved.
Follistatin effects
IGF-1 DES effects
Follistatin side effects
IGF-1 DES side effects
Follistatin dosing ranges
Research / muscle hypertrophy (recombinant)
100-300 mcg · Daily (SubQ) · 10-30 days per cycle
AAV gene therapy (clinical)
Single high-titer AAV infusion · One-time · Durable expression (years)
IGF-1 DES dosing ranges
Site-specific muscle hypertrophy
20-50 mcg per site · Into trained muscle post-workout (IM) · 30-50 days per cycle
General anabolic support
50-100 mcg · Once daily (SubQ) · 30-50 days per cycle
Follistatin: Endogenous activin/myostatin binding protein — the gene-therapy myostatin inhibitor. Typical dose 100-300 mcg. IGF-1 DES: Truncated IGF-1 variant — site-specific, short-acting muscle growth signal. Typical dose 20-100 mcg. Both fall under the Muscle Growth category.
Stacking Follistatin with IGF-1 DES is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Follistatin is typically dosed: Daily (SubQ) for Research / muscle hypertrophy (recombinant); One-time for AAV gene therapy (clinical). IGF-1 DES is typically dosed: Into trained muscle post-workout (IM) for Site-specific muscle hypertrophy; Once daily (SubQ) for General anabolic support.
Follistatin: Not FDA approved as recombinant protein. AAV-Follistatin gene therapy in clinical trials. IGF-1 DES: Not FDA approved.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free